Connect with us

Health

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Updates On Financial Status

Published

on

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) considers it can fund capital requirements and operations well into 2019. As of the close of September 30, 2017, the firm posted cash and cash equivalent of $66.3 million. An additional net proceeds of $3 million from shares offered in September and October 2017 as per its ATM plan was recorded in Q4 2017.

The buzz

Cannabinoids marks as a class of chemical compounds seen in the Cannabis crop. The two main cannabinoids comprised in Cannabis are cannabidiol and ∆9-tetrahydrocannabinol. Preclinical and clinical data support the prospect for CBD in curing epilepsy, FXS and other neuropsychiatric problem while THC can help cure tics.

Zynerba Pharmaceuticals is advancing therapeutic drugs that use unique transdermal know-hows that, if successful, may enable for controlled and sustained delivery of therapeutic levels of THC and CBD. Transdermal supply of cannabinoids may have gains over oral dosing as it enables the drug to be absorbed via the skin straight into the bloodstream.

This averts first-pass liver metabolism, probably allowing reduced dosage levels of active pharma ingredients with an increased bioavailability and enhanced safety profile. Transdermal delivery even avoids the gastrointestinal tract, reducing the opportunity for GI linked adverse events and the prospective degradation of Cannabidiol by gastric acid into ∆9-tetrahydrocannabinol, which may be linked with undesired psychoactive effects. Utilizing an established chemical pharma procedure for manufacturing, Zynerba Pharmaceuticals replicates the THC and CBD found in the Cannabis crop.

They consider that this will enable them to meet stringent international regulatory agencies’ standards while guaranteeing that they can efficiently supply the quantity of product required to fulfill the demand of the markets that the company is targeting.

In the last trading session, the stock price of Zynerba Pharmaceuticals declined more than 1% to close the day at $11.74. Post the last decline, the market cap of firm was noted at $159.12 million.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of MMJReporter.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure

BRANDS

DETAILS

SCORE

PRODUCT SITES

  • Certified Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49

9.8

30% OFF Today! “30 0FF”

  • All Natural
  • Made In U.S.A
  • Lab Tested
  • Price From $69

9.7

  • All Natural
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99

9.6

  • All Natural
  • Made In U.S.A
  • Oral Mist
  • Price From $39

9.5

BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Purity Promise
  • Price From $49
SCORE

9.8

PRODUCT SITE
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Lab Tested
  • Price From $69
SCORE

9.7

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Dissolvable Oral
  • Price From $99
SCORE

9.6

PRODUCT SITE VIEW PRODUCTS
BRAND
DETAILS
  • All Organic
  • Made In U.S.A
  • Oral Mist
  • Price From $39
SCORE

9.5

PRODUCT SITE VIEW PRODUCTS
Advertisement

Symbol        Alert        High        Gain

 

  VBIO          $0.67       $4.10      500%

  IMLFF        $0.11       $0.57      400%

  CMXC        $0.25       $0.45      80%

  REPCF       $0.54       $0.79      48%

 

Get Your Latest Winner Delivered to Your Inbox!

FREE

For The Next 48 Hours

Advertisement
Advertisement
Advertisement
Advertisement
Advertisement